Derek Haaland

707 total citations
18 papers, 306 citations indexed

About

Derek Haaland is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Derek Haaland has authored 18 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 7 papers in Immunology and 6 papers in Hematology. Recurrent topics in Derek Haaland's work include Rheumatoid Arthritis Research and Therapies (10 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Spondyloarthritis Studies and Treatments (5 papers). Derek Haaland is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Spondyloarthritis Studies and Treatments (5 papers). Derek Haaland collaborates with scholars based in Canada, Japan and United Kingdom. Derek Haaland's co-authors include Ilya Mukovozov, Danielle Baribeau, Jeffrey A. Siegel, Andrew S. Day, Anthony Otley, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Yuanyuan Duan and Ralph Lippe and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Journal of Pediatric Gastroenterology and Nutrition.

In The Last Decade

Derek Haaland

17 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Derek Haaland Canada 10 125 93 58 40 35 18 306
Piero Ruscitti Italy 7 107 0.9× 60 0.6× 74 1.3× 56 1.4× 20 0.6× 19 387
R. Tekaya Tunisia 8 187 1.5× 55 0.6× 67 1.2× 77 1.9× 25 0.7× 130 357
S. Bowyer United States 7 139 1.1× 61 0.7× 155 2.7× 88 2.2× 9 0.3× 9 487
Roland Duculan United States 14 73 0.6× 61 0.7× 14 0.2× 268 6.7× 29 0.8× 49 517
Roman Juřenčák Canada 8 115 0.9× 44 0.5× 168 2.9× 37 0.9× 7 0.2× 17 302
Yousra Ibn Yacoub Morocco 15 271 2.2× 127 1.4× 106 1.8× 45 1.1× 28 0.8× 28 422
Karima Benbouazza Morocco 11 197 1.6× 62 0.7× 82 1.4× 118 3.0× 11 0.3× 37 382
Fernando Martins Portugal 9 157 1.3× 53 0.6× 132 2.3× 75 1.9× 6 0.2× 23 364
Zheng Yu Xiao China 4 268 2.1× 95 1.0× 78 1.3× 41 1.0× 22 0.6× 5 387
Jorge Romaní Spain 12 87 0.7× 101 1.1× 25 0.4× 97 2.4× 7 0.2× 41 402

Countries citing papers authored by Derek Haaland

Since Specialization
Citations

This map shows the geographic impact of Derek Haaland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Haaland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Haaland more than expected).

Fields of papers citing papers by Derek Haaland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek Haaland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Haaland. The network helps show where Derek Haaland may publish in the future.

Co-authorship network of co-authors of Derek Haaland

This figure shows the co-authorship network connecting the top 25 collaborators of Derek Haaland. A scholar is included among the top collaborators of Derek Haaland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek Haaland. Derek Haaland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2025). POS0835 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 5-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 84. 980–981.
2.
3.
Tanaka, Yoshiya, Tsutomu Takeuchi, Derek Haaland, et al.. (2023). Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials. International Journal of Rheumatic Diseases. 26(7). 1248–1259. 8 indexed citations
4.
Bykerk, Vivian P., Peter Nash, David G. Nicholls, et al.. (2023). Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data. Rheumatology and Therapy. 10(3). 693–706. 1 indexed citations
5.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2022). Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatology and Therapy. 10(1). 275–292. 28 indexed citations
6.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2022). POS0081 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 81. 260–261. 1 indexed citations
7.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2021). AB0523 LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 80. 1288–1289. 4 indexed citations
8.
Kavanaugh, Arthur, Philip J. Mease, Frank Behrens, et al.. (2021). AB0547 ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES. Annals of the Rheumatic Diseases. 80. 1306–1307. 1 indexed citations
9.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2021). Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 7(3). e001838–e001838. 58 indexed citations
10.
Rahman, Proton, Michael Starr, Derek Haaland, et al.. (2020). Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry. BMC Rheumatology. 4(1). 56–56. 3 indexed citations
11.
Barra, Lillian, Janet Pope, Priscila Pequeno, et al.. (2020). Incidence and prevalence of giant cell arteritis in Ontario, Canada. Lara D. Veeken. 59(11). 3250–3258. 12 indexed citations
12.
Bessette, Louis, Boulos Haraoui, Andrew Chow, et al.. (2019). Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study. Therapeutic Advances in Musculoskeletal Disease. 11. 1759720X19831151–1759720X19831151. 10 indexed citations
13.
Haaland, Derek, et al.. (2016). Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous. BMJ Case Reports. 2016. bcr2016215423–bcr2016215423. 18 indexed citations
14.
Haaland, Derek & Jeffrey A. Siegel. (2016). Quantitative filter forensics for indoor particle sampling. Indoor Air. 27(2). 364–376. 23 indexed citations
15.
Haaland, Derek, Andrew S. Day, & Anthony Otley. (2013). Development and Validation of a Pediatric IBD Knowledge Inventory Device. Journal of Pediatric Gastroenterology and Nutrition. 58(3). 313–319. 34 indexed citations
16.
Haaland, Derek, Dana Cohen, Courtney Kennedy, et al.. (2009). Closing the osteoporosis care gap – Increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatrics. 9(1). 28–28. 36 indexed citations
17.
Haaland, Derek, et al.. (2008). The Relationship Between Exercise and Osteoarthritis in the Elderly. Clinical Journal of Sport Medicine. 18(6). 508–521. 19 indexed citations
18.
Haaland, Derek, et al.. (2008). Is Regular Exercise a Friend or Foe of the Aging Immune System? A Systematic Review. Clinical Journal of Sport Medicine. 18(6). 539–548. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Piero Ruscitti Breakdown of academic impact, for papers by R. Tekaya Breakdown of academic impact, for papers by S. Bowyer Breakdown of academic impact, for papers by Roland Duculan Breakdown of academic impact, for papers by Roman Juřenčák Breakdown of academic impact, for papers by Yousra Ibn Yacoub Breakdown of academic impact, for papers by Karima Benbouazza Breakdown of academic impact, for papers by Fernando Martins Breakdown of academic impact, for papers by Zheng Yu Xiao Breakdown of academic impact, for papers by Jorge Romaní
Rankless by CCL
2026